Related Research Articles
Robert Samuel Langer Jr. FREng is an American chemical engineer, scientist, entrepreneur, inventor and one of the twelve Institute Professors at the Massachusetts Institute of Technology.
M. Krishnan Nair was an Indian oncologist. He was the founding director of the Regional Cancer Centre, Thiruvananthapuram, a director of the S.U.T. Institute of Oncology, and Trivandrum Cancer Center(TCC), part of SUT Royal Hospital in Thiruvananthapuram (Trivandrum) and a professor at the Amrita Institute of Medical Sciences & Research in Kochi. The Government of India awarded him the fourth highest civilian award of the Padma Shri, in 2001 for his contributions in the cancer care field.
Josep Baselga i Torres, known in Spanish as José Baselga was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein which is impacted in aggressive breast cancers.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
Robert Anthony "Robin" Weiss is a British molecular biologist, Professor of Viral Oncology at University College London and a member of the Nuffield Council on Bioethics.
Evofosfamide is an investigational hypoxia-activated prodrug that is in clinical development for cancer treatment. The prodrug is activated only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.
John Mendelsohn was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research.
Michael John Peckham was a British oncologist and artist. As a cancer physician he is best known for his contribution to the treatment of testicular cancer. His paintings were first exhibited in 1962 and he showed in numerous mixed and solo exhibitions.
Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.
Johannes (Hans) Carolus Clevers is a Dutch molecular geneticist, cell biologist and stem cell researcher. He became the Head of Pharma, Research and Early Development, and a member of the Corporate Executive Committee, of the Swiss healthcare company Roche in 2022. Previously, he headed a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research and at the Princess Máxima Center; he remained as an advisor and guest scientist or visiting researcher to both groups. He is also a Professor in Molecular Genetics at the University of Utrecht.
Roeland "Roel" Nusse is a professor at Stanford University and an investigator at the Howard Hughes Medical Institute. His research was seminal in the discovery of Wnt signaling, a family of pleiotropic regulators involved in development and disease.
Patrick Schöffski is a German medical doctor specializing in internal medicine, hematology and medical oncology.
Paul Alan Marks was a medical doctor, researcher and administrator. He was a faculty member and president at Memorial Sloan Kettering Cancer Center.
Takashi Sugimura was a Japanese biochemist, famous for research on chemical carcinogens. He received the Japan Prize for the contribution to establishment of fundamental concept on causes of cancer. He was elected as President of the Japan Academy on October 15, 2013, serving till 2016 and was replaced with Hiroshi Shiono.
Professor Richard James Gilbertson is a paediatric oncology clinician scientist and a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. He is the Li Ka Shing Chair of Oncology, and Director of the CRUK Cambridge Major Centre and the Children’s Brain Tumour Centre of Excellence.
Jacques (Sjaak) Neefjes is a Dutch scientist who made breakthroughs in several research disciplines such as immunology, cell biology, chemistry, cancer biology, microbiology, and epidemiology. He is a professor at the Leiden University Medical Center. In 2020 he was one of four winners of the Spinoza Prize.
Bob Löwenberg is a clinical hematologist/investigator. He is Professor of Hematology at Erasmus University Rotterdam.
Cornelis Joseph Maria Melief is a globally recognised immunology expert specialising in cancer immunology and immunotherapy, with special focus on therapeutic cancer vaccines. He is Emeritus Professor, former head of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center, and Chief Scientific Officer at ISA Therapeutics in Netherlands. He is known for his work in the field of cancer immunology, devising new cancer therapies based on the activation of the patient’s own immune system.
References
- ↑ "Jaap Verweij". European Society for Medical Oncology . Retrieved 27 August 2020.
- ↑ "The Cancer Drug Development Forum". Organizational Structure. Retrieved 27 August 2020.
- ↑ "Past Presidents". Connective Tissue Oncology Society. Retrieved 30 August 2020.
- ↑ "JAAP VERWEIJ". Royal Netherlands Academy of Arts and Sciences . Retrieved 20 September 2020.
- ↑ "J. Verweij". Semantic Scholar . Retrieved 27 August 2020.
   | This biographical article related to medicine in the Netherlands is a stub. You can help Wikipedia by expanding it. |